Products

The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records

Radiopharmaceuticals

FP-CIT
Indication Diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine carriers in the brain striatum
Features World's first brain imaging tracer related to Parkinson's disease

*DuChemBio owns all FP-CIT license and rights for the technology & clinical data package worldwide except Korea

F-DOPA
Indication Diagnosis of tumors that cannot be diagnosed with conventional FDG, mainly brain tumors and additionally neuroendocrine tumors, pheochromocytoma
Features The world's first Radiopharmaceutical for brain tumor diagnosis with neutralization technology
Neuraceq
Indication Diagnosis of Alzheimer's Disease by measurement of beta-amyloid distribution and density in the brain
Features First Radiopharmaceutical in Asia for diagnosis of beta amyloid in Alzheimer's disease which is essential for differentiation from vascular dementia
VIZAMYL
Indication PET imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline
Features the only amyloid imaging agent with FDA approval for color image interpretation
Enables consistency and clinical diagnostic certainty in interpretation of scans
PI-2620
Indication Brain PET imaging for tau pathology detection in adult patients who are being evaluated for neurodegenerative decline such as Alzheimer’s Disease (AD) and progressive supranuclear palsy (PSP)
Features “second-generation” tau tracer that strongly binds to 4R tau found in non-AD tauopathies
MK-6240
Indication Tau PET tracer designed to detect the neurofibrillary tangles in the brains of patients with Alzheimer's Disease
Features Highly sensitive second generation tracer that can detect tangles early on and SUVR uptake concords with 6-stage BRAAK model for staging AD.
FES
Indication Diagnosis of metastatic breast cancer and determination of estrogen receptor status
Features The world's first Radiopharmaceutical for breast cancer diagnosis
FACBC
Indication Diagnostic imaging of recurrent or metastatic prostate cancer
Features Radiopharmaceutical for prostate cancer diagnosis
FDG
Indication Diagnosis of tumors that metabolize glucose
Features Radiopharmaceuticals for the diagnosis of tumors, which contributed to the birth of the Radiopharmaceutical industry
NaF
Indication Diagnostic imaging of bone to identify altered osteogenic active areas
Features Radiopharmaceutical for the diagnosis of bone-related diseases
68Ga-PSMA-11
Indication Primary staging of high-risk prostate cancer and detection of metastases in patients with suspected biochemical recurrence;
patient selection for treatment with PSMA TRLP & monitoring of response to systemic treatment
Features Radiopharmaceutical for prostate cancer staging and diagnosis using molecularly targeted radiation (MTR)

그누보드5
Address 6,7F, 81, Wausan-ro, Mapo-gu, Seoul, Republic of Korea [04041]
Tel 02 332 4868 Fax 02 323 3437

Copyright © 2021, DuchemBio, Co., Ltd. All Rights Reserved